Relationship between immunological rejection and matrix GLA protein in cryopreserved vascular allografts.
BACKGROUND
Cryopreserved tissue allografts used for cardiovascular diseases become calcified as a late complication after transplantation, probably caused by immunological rejection. Recent attention has been focused on the inhibitory effect of matrix Gla protein (MGP) on ectopic vascular calcification, but the behavior of MGP in cryopreserved allografts is uncertain. In this study we examined the relationship between immunological rejection and MGP in cryopreserved rat aortic grafts after transplantation.


METHODS
Cryopreserved rat aortae were isografted or allografted intraperitoneally. Fresh isografts were also tested. The grafts were retrieved 9 days after transplantation and the intragraft MGP mRNA was measured by a real-time quantitative PCR method. The effect of daily administration of FK506 on MGP mRNA levels in cryopreserved isografts and allografts after transplantation was also evaluated.


RESULTS
There was no significant difference in intragraft MGP mRNA levels between fresh and cryopreserved isografts 9 days after transplantation. MGP expression levels in cryopreserved allografts were significantly lower as compared to those in cryopreserved isografts (P < .01). Daily administration of FK506 enhanced intragraft MGP mRNA (ninefold) in cryopreserved allografts (P < .01), but not in cryopreserved isografts.


CONCLUSIONS
Immunological rejection is likely to inhibit MGP expression in cryopreserved vascular allografts, resulting in late-onset calcification.
Kiji
T
T
Department of Surgery III, Nara Medical University, Nara, Japan. t-kiji@naramed-u.ac.jp
Dohi
Y
Y
Nishizaki
K
K
Sakaguchi
H
H
Nagasaka
S
S
Hayata
Y
Y
Yonemasu
K
K
Taniguchi
S
S
D000818:Animals; D001011:Aorta / Q000637:transplantation*; D002135:Calcium-Binding Proteins / Q000235:genetics*; D015925:Cryopreservation; D016326:Extracellular Matrix Proteins / Q000235:genetics*; D006084:Graft Rejection / Q000276:immunology*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D016133:Polymerase Chain Reaction; D012333:RNA, Messenger / Q000235:genetics; D051381:Rats; D011914:Rats, Inbred BN; D011917:Rats, Inbred Lew; D016559:Tacrolimus / Q000627:therapeutic use; D014184:Transplantation, Homologous / Q000276:immunology; D000097568:Matrix Gla Protein
D002135:Calcium-Binding Proteins; D016326:Extracellular Matrix Proteins; D007166:Immunosuppressive Agents; D012333:RNA, Messenger; D016559:Tacrolimus; D000097568:Matrix Gla Protein